-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Bright Minds Biosciences, Raises Price Target to $145

Benzinga·03/04/2026 16:04:53
Listen to the news
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and raises the price target from $115 to $145.